CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Ondine Biomedical Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Ondine Biomedical Inc
888-1100 Melville Street
Phone: (604) 669-0555p:604 669-0555 Vancouver, BC  V6E 4A6  Canada Ticker: OBPOBP
On 9/6/2011, Ondine Biomedical Inc. has executed a plan of arrangement pursuant to which 0902337 B.C. Ltd., a private company whose sole shareholder is Carolyn Cross, Chairman and Chief Executive Officer of Ondine, has acquired all of the issued and outstanding common shares of Ondine.
This company is no longer actively traded on any major stock exchange.
Business Summary
Ondine Biomedical Inc., formerly Ondine Biopharma Corporation, is a medical device company developing photodisinfection based products. The Company is developing non-antibiotic therapies for the treatment of a spectrum of bacterial, fungal and viral infections. The Company focuses on developing products utilizing its light-activated technology, primarily for the hospital acquired infection market. Periowave is a commercial product developed by the Company utilizing its PDD platform technology. It is a non-invasive approach to the treatment of periodontal disease in adults. It focuses on MRSAid and the photodynamic endotracheal tube treatment (PETT) System to prevent Ventilator-associated pneumonia designed for the hospital acquired infection market. On December 7, 2009, it acquired Advanced Photodynamic Technologies, Inc. In September 2010, the Company completed the sale of a majority interest in Sinuwave Technologies Corporation.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/201112/31/2010Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2835 In vitro and in vivo diagnostic substances
2833 Medicinal chemicals and botanical products
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer CarolynCross 1/6/2009 12/1/2004
President, Chief Technology Officer Nicolas G.Loebel 1/6/2009 3/1/2004
Chief Financial Officer, Vice President - Finance, Corporate Secretary WilliamHarper 8/1/2006 7/1/2005
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Advanced Photodynamic Technologies, Inc.
OBP
Ondine Biopharma Corp.
Ondine Biopharma Corporation

General Information
Number of Employees: 18 (As of 12/31/2010)
Outstanding Shares: 9,661,468 (As of 8/10/2011)
Stock Exchange: TSE
Fax Number: (604) 669-0533


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023